Drug Combination on Exercise Performance at High Altitude

Phase 3CompletedNCT01902758

University of Montana28 enrolled

Overview

This study is being conducted to determine the effectiveness of using two FDA approved medications in concert to reduce the likelihood of sickness due to low oxygen levels and to reduce the decrement in physical performance at higher elevations. The investigators hypothesize that this drug combination will reduce the symptoms of acute mountain sickness and improve exercise performance at high altitude compared to placebo.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Masking

TRIPLE

Enrollment

Conditions

Acute Mountain Sickness

Interventions

ambrisentan and theophyllineDRUG

placeboDRUG

placebo for comparison group

Eligibility

Sex: MALEMin age: 18 YearsMax age: 45 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * healthy males Exclusion Criteria: * VO2max below 45ml/kg/min * currently taking any medication

Locations (1)

Montana Center for Work Physiology and Exercise Metabolism

Missoula, Montana, United States

Outcomes

Primary Outcomes

Time (Minutes) to Complete 2 Miles on a Treadmill

Time frame: after arriving at high altitude (within 1 hour)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.